Antimicrobial Resistance

Petri Dish

RB to support the World Health Organisation’s strategic framework to combat Antimicrobial Resistance (AMR)

Antimicrobial resistance (AMR) is a growing public health concern worldwide.

The inappropriate use of antibiotics for respiratory tract infections contributes to the development of AMR, and as many as 79 per cent of antibiotics prescribed for acute respiratory tract infections may be unnecessary (Scott 2007).

As a global market leader in the treatment of sore throat, with our brand Strepsils, RB has the expertise, scale and responsibility to take an active role in helping to reduce antibiotic misuse for respiratory illnesses.

In 2012, RB founded the ‘Global Respiratory Infection Partnership’ (GRIP www.grip-initiative.org), an expert-led initiative created to educate and support medical professional stakeholders on the issue of antibiotic misuse for respiratory illnesses like sore throat, common colds and cough.

At RB, we believe that consumers, when equipped with the right education, should be empowered to drive their own health, wellness and relief. Therefore, beyond the GRIP initiative, our goal is to drive consumer awareness, understanding and behaviour change related to appropriate antibiotic usage for respiratory tract infections, and reduce the number of sore throats that are inappropriately treated with antibiotics.

Consumer education on appropriate symptomatic management of respiratory infections coupled with good hygiene practices are very much part of the World Health Organization’s (WHO) Global Action Plan on AMR, which aims to contain AMR.

RB is proud to play a role in support of the WHO’s Global Action Plan, and in particular the WHO’s Antibiotic Awareness Week, by educating consumers and supporting professionals to reduce antibiotic misuse for respiratory illnesses.

Frequently Asked Questions

Find out more on why and since when RB has been involved in efforts to reduce antimicrobial resistance.

Why is antimicrobial resistance a concern?

Antimicrobial resistance (AMR) is a growing public health concern worldwide. In fact, the World Health Organization estimates that antibiotic-resistant infections already kill 700,000 people a year globally with predictions of this reaching 10 million by 2050. That’s why we support and enable responsible self-care by offering a variety of products that reduce the unnecessary treatment of sore throats with antibiotics by encouraging over the counter remedies and treatments for respiratory illness.

What causes/contributes to the problem of AMR?

The inappropriate use of antibiotics for respiratory tract infections contributes to the development of antimicrobial resistance. In fact, as many as 79 percent of antibiotics prescribed for acute respiratory tract infections are unnecessary, and Further, antibiotics will not work for 9 out of 10 sore throats because they are caused by self-limiting viral infections.

How long has RB been involved in efforts to reduce antimicrobial resistance?

RB has a long history of supporting many industry associations that have direct relevance to the issue of AMR. The latest campaign from our Strepsils brand builds on a five-year healthcare professional educational initiative called the Global Respiratory Infection Partnership (GRIP), and aims to raise awareness of and reduce the inappropriate treatment of many sore throats with antibiotics by encouraging over the counter symptomatic treatments for respiratory illness.

We are proud to support the World Health Organization’s World Antibiotic Awareness Week and endorse their strategic framework, which aims to contain AMR and furthers our common goal of tackling antibiotic resistance and misuse.

Why is RB taking on the issue of antimicrobial resistance?

Antimicrobial resistance is a growing public health concern worldwide that kills an estimated 700,000 people a year globally with predictions of this reaching 10 million by 2050. Given the complexity and scale of this issue, we need an integrated response from national governments and health systems, healthcare professionals, industry, and individuals in order to further our common goal of tackling antibiotic resistance and misuse.

As a global market leader and expert in the treatment of sore throats, Strepsils has the scale, authority and responsibility to educate consumers on why antibiotic misuse matters and what they can personally do about it to bring about a change in their behavior.

As a global consumer health and hygiene company, RB has a responsibility to bring together private sector expertise and third-party organizations dedicated to this issue to ensure consumers get effective treatment for their symptoms, and alleviate unnecessary strain on our healthcare systems.

More about Global Respiratory Infection Partnership

Follow www.grip-initiative.org to find out more about the Global Respiratory Infection Partnership.